Moreover, CAR-T cells targeting CD19, GD2 or B7H3 for CNS and non-CNS cancers induced white matter microglial reactivity with persistent neuroinflammation, dysfunction of oligodendroglial cells and restricted hippocampal neurogenesis in several mouse models, resulting in long-term cognitive impairment.5 Additionally, microglial and oligodendroglial reactivity were detected also during post-mortem examination of the frontal cortex and subcortical white matter of patients treated with anti-GD2 CAR-T cell therapy for brainstem tumors. Here, CD19 is linked to Cognitive impairment.